Literature DB >> 8204349

Subsequent primary cancers following bladder cancer.

E Salminen1, E Pukkala, L Teppo, S Pyrhönen.   

Abstract

The incidence of a subsequent primary cancer was investigated among 10,014 patients with cancer of the urinary bladder diagnosed in 1953-1989 in Finland. During the follow-up period of 1953-1989, 652 new metachronous cancers were diagnosed. The number equals the expected number based on the national incidence figures. There were 195 second cancers of the lung. The standardised incidence ratio (SIR) for lung cancer was 1.3 among males [95% confidence interval (CI) 1.1-1.4] and 2.6 among females (95% CI 1.4-4.5). An increased SIR for larynx cancer in males (SIR = 1.7, 95% CI 0.91-2.8) and for kidney cancer in females (SIR = 3.6, 95% CI 1.8-6.2) was observed. The risk of a second cancer was greater among patients less than 60 years of age at the time of first diagnosis than among older patients. No consistent differences were observed in the risk of new cancer between bladder cancer patients treated with or without radiotherapy.

Entities:  

Mesh:

Year:  1994        PMID: 8204349     DOI: 10.1016/0959-8049(94)90246-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

1.  Urothelial cancer and the diagnosis of subsequent malignancies.

Authors:  Deepak K Pruthi; Zoann Nugent; Piotr Czaykowski; Alain A Demers
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

2.  Is there evidence for a multidisciplinary follow-up after urological cancer? An evaluation of subsequent cancers.

Authors:  M J Mathers; J Zumbe; S Wyler; S Roth; M Gerken; F Hofstädter; T Klotz
Journal:  World J Urol       Date:  2008-04-18       Impact factor: 4.226

3.  [Interdisciplinary oncologic after-care exemplified by second primary tumors after bladder carcinoma].

Authors:  T Klotz; F Hofstädter; M Gerken
Journal:  Urologe A       Date:  2003-06-25       Impact factor: 0.639

4.  Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites.

Authors:  Joo Hoon Kim; Sun Young Rha; Chan Kim; Gun Min Kim; Sang Hyun Yoon; Ki Hyang Kim; Min Jae Kim; Joong Bae Ahn; Hyun Cheol Chung; Jae Kyung Roh; Hyo Song Kim
Journal:  Cancer Res Treat       Date:  2010-12-31       Impact factor: 4.679

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.